These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11910290)

  • 1. Neutral endopeptidase inhibition: the potential of a new therapeutic approach in cardiovascular disease evolves.
    Veelken R; Schmieder RE
    J Hypertens; 2002 Apr; 20(4):599-603. PubMed ID: 11910290
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
    Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
    J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats.
    Thöne-Reinke C; Simon K; Richter CM; Godes M; Neumayer HH; Thormählen D; Hocher B
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S76-9. PubMed ID: 15838365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multitarget cardiovascular drugs.
    Trstenjak U; Kikelj D
    Curr Med Chem; 2011; 18(17):2531-42. PubMed ID: 21568894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
    Battistini B; Daull P; Jeng AY
    Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Trapani AJ; Beil ME; Bruseo CW; Savage P; Firooznia F; Jeng AY
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S211-5. PubMed ID: 15838282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?
    Rabelink TJ; Stroes ES; Bouter KP; Morrison P
    Cardiovasc Res; 1998 Sep; 39(3):543-9. PubMed ID: 9861295
    [No Abstract]   [Full Text] [Related]  

  • 8. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics.
    Molinaro G; Rouleau JL; Adam A
    Curr Opin Pharmacol; 2002 Apr; 2(2):131-41. PubMed ID: 11950623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats.
    Daull P; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S398-401. PubMed ID: 15838331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
    Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11.
    Trapani AJ; De Lombaert S; Kuzmich S; Jeng AY
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S69-71. PubMed ID: 8587471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.
    Dai ZK; Hsieh CC; Chai CY; Wu JR; Jeng AY; Chou SH; Wu BN; Yeh JL; Chen IJ; Tan MS
    Pediatr Pulmonol; 2010 Nov; 45(11):1076-85. PubMed ID: 20658482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual endothelin-converting enzyme/neutral endopeptidase inhibition: a novel treatment for renovascular hypertension beyond blood pressure lowering?
    Dhaun N; Webb DJ
    Hypertension; 2011 Apr; 57(4):667-9. PubMed ID: 21339473
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival.
    Wengenmayer C; Krikov M; Mueller S; Lucht K; Villringer A; Hocher B; Unger T; Thoene-Reineke C
    Neurol Res; 2011 Mar; 33(2):201-7. PubMed ID: 21801596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
    Lin CL; Winardi W; Jeng AY; Kwan AL
    Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition.
    Mellin V; Jeng AY; Monteil C; Renet S; Henry JP; Thuillez C; Mulder P
    J Cardiovasc Pharmacol; 2005 Sep; 46(3):390-7. PubMed ID: 16116347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual endothelin-converting enzyme/neutral endopeptidase blockade in rats with D-galactosamine-induced liver failure.
    Hocher B; Heiden S; von Websky K; Rahnenführe J; Kalk P; Pfab T
    Eur J Med Res; 2011 Jun; 16(6):275-9. PubMed ID: 21810562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors.
    Love MP; Haynes WG; Gray GA; Webb DJ; McMurray JJ
    Circulation; 1996 Nov; 94(9):2131-7. PubMed ID: 8901663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.